These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 14727316)

  • 1. Severe intoxication after phenytoin infusion: a preventable pharmacogenetic adverse reaction.
    Lardizabal DV; Lüders HO; Hovinga CA; Bourgeois BF
    Neurology; 2004 Jan; 62(1):161; author reply 161. PubMed ID: 14727316
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe intoxication after phenytoin infusion: a preventable pharmacogenetic adverse reaction.
    Privitera MD; Welty T
    Neurology; 2004 Jan; 62(1):161; author reply 161. PubMed ID: 14718732
    [No Abstract]   [Full Text] [Related]  

  • 3. Severe intoxication after phenytoin infusion: a preventable pharmacogenetic adverse reaction.
    Citerio G; Nobili A; Airoldi L; Pastorelli R; Patruno A
    Neurology; 2003 Apr; 60(8):1395-6. PubMed ID: 12707459
    [No Abstract]   [Full Text] [Related]  

  • 4. Cardiac arrest after fast intravenous infusion of phenytoin mistaken for fosphenytoin.
    DeToledo JC; Lowe MR; Rabinstein A; Villaviza N
    Epilepsia; 2001 Feb; 42(2):288. PubMed ID: 11240605
    [No Abstract]   [Full Text] [Related]  

  • 5. [Plasma separation in acute, intravenous phenytoin poisoning].
    Scharf J; Ruder H; Harms D
    Monatsschr Kinderheilkd; 1990 Apr; 138(4):227-30. PubMed ID: 2113180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P450 2C18 catalyzes the metabolic bioactivation of phenytoin.
    Kinobe RT; Parkinson OT; Mitchell DJ; Gillam EM
    Chem Res Toxicol; 2005 Dec; 18(12):1868-75. PubMed ID: 16359177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Warfarin sensitivity and genetic polymorphisms: should pharmacokinetic screening be part of anticoagulant dosing decisions?
    Baglin TP
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):656-7. PubMed ID: 16258463
    [No Abstract]   [Full Text] [Related]  

  • 8. Acenocoumarol and phenytoin toxicity in the presence of CYP2C9 mutation.
    Jose L; Binila C; Chandy SJ; Mathews JE; Mathews KP
    J Assoc Physicians India; 2008 Apr; 56():250-2. PubMed ID: 18702389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Warfarin resistance with poor CYP2C9 activity and CYP2C9*1*2 genotype.
    Dericioglu N; Babaoglu MO; Saygi S; Bozkurt A; Yasar U
    Ann Pharmacother; 2004 May; 38(5):899. PubMed ID: 15039471
    [No Abstract]   [Full Text] [Related]  

  • 10. Genetic factors associated with severe cutaneous adverse reactions.
    Lozano R
    JAMA; 2014 Nov; 312(20):2165-6. PubMed ID: 25423224
    [No Abstract]   [Full Text] [Related]  

  • 11. Genetic factors associated with severe cutaneous adverse reactions--reply.
    Chung WH; Hung SI
    JAMA; 2014 Nov; 312(20):2166. PubMed ID: 25423226
    [No Abstract]   [Full Text] [Related]  

  • 12. The frequency of cytochrome P450 2C9 genetic variants in the Russian population and their associations with individual sensitivity to warfarin therapy.
    Pchelina SN; Sirotkina OV; Taraskina AE; Vavilova TV; Shwarzman AL; Schwartz EI
    Thromb Res; 2005; 115(3):199-203. PubMed ID: 15617742
    [No Abstract]   [Full Text] [Related]  

  • 13. Rx for medication errors. A patient medication safety plan can help prevent the cascade of devastating and preventable complications from adverse drug events.
    Friedley NJ
    Med Econ; 2008 Oct; 85(20):34-8. PubMed ID: 19049229
    [No Abstract]   [Full Text] [Related]  

  • 14. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance.
    Totah RA; Rettie AE
    Clin Pharmacol Ther; 2005 May; 77(5):341-52. PubMed ID: 15900280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A prolonged severe intoxication after ingestion of phenytoin and phenobarbital.
    Albertson TE; Fisher CJ; Shragg TA; Baselt RC
    West J Med; 1981 Nov; 135(5):418-22. PubMed ID: 7340137
    [No Abstract]   [Full Text] [Related]  

  • 16. Rationalization of an antiepileptic drug formulation.
    Gulati S; Sriram CS; Kalra V
    Indian Pediatr; 2002 Sep; 39(9):826-9. PubMed ID: 12368526
    [No Abstract]   [Full Text] [Related]  

  • 17. CYP2C9 genotype as a predictor of drug disposition in humans.
    Lee CR
    Methods Find Exp Clin Pharmacol; 2004; 26(6):463-72. PubMed ID: 15349140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9.
    Sachse-Seeboth C; Pfeil J; Sehrt D; Meineke I; Tzvetkov M; Bruns E; Poser W; Vormfelde SV; Brockmöller J
    Clin Pharmacol Ther; 2009 Mar; 85(3):273-6. PubMed ID: 19005461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse drug reactions and avalanches: life at the edge of chaos.
    Frattarelli DA
    J Clin Pharmacol; 2005 Aug; 45(8):866-71. PubMed ID: 16027396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypothermia and phenytoin toxicity.
    Newberger DS; Blyth SA
    Clin Neuropharmacol; 2003; 26(4):172-3. PubMed ID: 12897633
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.